Pharmaceuticals

Incannex Healthcare

Incannex Healthcare Inc. Obtains FDA's Fast Track Designation for IHL-42X

Incannex Healthcare released FY2026 Q1 earnings on November 14 EST, actual revenue USD 0 (forecast USD 203.28 K), actual EPS USD -0.0206 (forecast USD -0.3966)

Incannex Healthcare Announces 2025 Annual General Meeting Schedule

Incannex Healthcare released FY2025 Q4 earnings on September 29 (EST), actual revenue USD 0 (forecast USD 201.62K), actual EPS USD -0.3802 (forecast USD -0.2929)

Incannex Healthcare released FY2025 earnings on September 29 (EST), actual revenue USD 86K (forecast USD 201.62K), actual EPS USD -1.3607 (forecast USD -0.9689)

Incannex Reports Positive Trial Results for Psilocybin-Assisted Therapy for Generalized Anxiety Disorder

Incannex Healthcare's Board Approves Up To $20 Million Stock Repurchase Plan

Incannex Healthcare's OSA Treatment Drug Shows Promising Phase II Trial Results

Incannex Reports Positive Phase 2 Results for IHL-42X

Incannex Healthcare Hires Expert to Advance Sleep Apnea Therapy

Incannex Healthcare Makes Key Milestone in OSA Drug Phase II Trial

Incannex and Mind Medicine Form JV to Establish Psychedelic-Assisted Therapy Clinic

Incannex Healthcare Inc. stock transferred from NASDAQ Global Market to NASDAQ Capital Market

Incannex Healthcare Cancels A-Round Warrants

Incannex Expands OSA Program Advisory Board

Incannex Healthcare advances IHL-42X Reposa trial to Phase 3

Incannex Healthcare Cancels Series A Warrants to Reduce Potential Dilution

Incannex Healthcare Expands Stock Issuance Plan

Incannex Healthcare Announces Cancellation of A Series Warrants

Incannex Expands Share Issuance to Raise Funds

Beasley Broadcast

NXG CUSHING MIDSTREAM ENERGY F COM 0.001(S/R 11/12/2025)

HeartBeam

Enveric Biosciences

Biodexa Pharmaceuticals

A SPAC III Acquisition

Irobot

Creative Global Tech

Mawson Infrastructure

Photronics

Eli Lilly

ROCHE HOLDINGS AG

Roche

Astrazeneca

NOVARTIS AG

Novo Nordisk AS

Chugai Pharmaceutical

UCB S.A.

Daiichi Sankyo

Otsuka Pharmaceutical

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap